Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 diabetes and obesity.

With the obesity and Type 2 diabetes markets growing at unprecedented rates, the GLP-1 receptor agonist market is also growing.

In a recently published report, leading data and analytics company GlobalData estimates that GLP-1 receptor agonist sales for the Type 2 diabetes and obesity markets will reach more than $125bn in 2033.

According to GlobalData’s GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: Seven-Market Forecast and Market Analysis report, GLP-1 receptor agonists (including dual and triple agonists or combination therapies including a GLP-1R agonist) will dominate the metabolic diseases space over the next ten years.

These medicines are already popular and key opinion leaders (KOLs) interviewed by GlobalData say that patients usually ask their doctors for these specific medicines.

There are currently ten GLP-1 receptor agonists approved for Type 2 diabetes and three for obesity, but many more are expected to reach the market in the next five to ten years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Indeed, there are 51 products in clinical development for obesity or Type 2 diabetes that exploit the GLP-1 receptor agonist mechanism, often coupled with other actions.

At the moment more than 190 million people live with Type 2 diabetes or obesity in the seven major markets analysed in GlobalData’s study (7MM: US, France, Germany, Italy, Spain, UK, and Japan), and these numbers are set to grow at an annual growth rate of 1.35% and 0.57% for Type 2 diabetes and obesity, respectively, in the next ten years.

With the increase in physicians’ and patients’ awareness of obesity as a disease, and stronger trust in the long-term effects and safety of GLP-1 receptor agonists, the uptake of these medicines is expected to increase.

Therefore, marketed and pipeline GLP-1 receptor agonists expected to enter the 7MM for Type 2 diabetes or obesity within the next ten years are expected to hit $125bn in sales at the end of the forecast period.

At present, the market is dominated by Novo Nordisk and Eli Lilly, which have developed the famous Ozempic/Wegovy and Mounjaro/Zepbound, respectively.

However, the market offers the opportunity for other players to enter the space, as the patient population that can benefit from this type of molecule is so large.

GLP-1 receptor agonists are also being investigated for other types of diseases such as metabolic-associated steatohepatitis and chronic kidney disease, and even neurological diseases, including Alzheimer’s and Parkinson’s.

Thus, the GLP-1 market could grow even further, currently showing great potential in multiple disease areas.